The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

M Gnant; G Pfeiler; H Stöger; Brigitte Mlineritsch; F Fitzal; M Balic; W Kwasny; M Seifert; M Stierer; P Dubsky; Richard Greil; G Steger; H Samonigg; C Fesl; R Jakesz

doi:10.1038/bjc.2013.367

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

M Gnant, G Pfeiler, H Stöger, Brigitte Mlineritsch (Co-author), F Fitzal, M Balic, W Kwasny, M Seifert, M Stierer, P Dubsky, Richard Greil (Co-author), G Steger, H Samonigg, C Fesl, R Jakesz

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

51 Citations (Web of Science)

Original language	English
Pages (from-to)	58-96
Journal	BRITISH JOURNAL OF CANCER
Volume	109
Issue number	3
DOIs	https://doi.org/10.1038/bjc.2013.367
Publication status	Published - 2013

Keywords

AUSTRIAN BREAST
THERAPY
TAMOXIFEN
LETROZOLE
WOMEN
AMINOGLUTETHIMIDE
RECURRENCE
SURVIVAL
PROJECT
OBESITY

Access to Document

10.1038/bjc.2013.367

Cite this

Gnant, M., Pfeiler, G., Stöger, H., Mlineritsch, B., Fitzal, F., Balic, M., Kwasny, W., Seifert, M., Stierer, M., Dubsky, P., Greil, R., Steger, G., Samonigg, H., Fesl, C., & Jakesz, R. (2013). The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. BRITISH JOURNAL OF CANCER , 109(3), 58-96. https://doi.org/10.1038/bjc.2013.367

Gnant, M ; Pfeiler, G ; Stöger, H et al. / The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. In: BRITISH JOURNAL OF CANCER 2013 ; Vol. 109, No. 3. pp. 58-96.

@article{14a31261c5a14f21b777a8dd174044f2,

title = "The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.",

keywords = "AUSTRIAN BREAST, THERAPY, TAMOXIFEN, LETROZOLE, WOMEN, AMINOGLUTETHIMIDE, RECURRENCE, SURVIVAL, PROJECT, OBESITY",

author = "M Gnant and G Pfeiler and H St{\"o}ger and Brigitte Mlineritsch and F Fitzal and M Balic and W Kwasny and M Seifert and M Stierer and P Dubsky and Richard Greil and G Steger and H Samonigg and C Fesl and R Jakesz",

note = "IIIrd Medical Department with Hematology and Medical Oncology, Hemostaeology, Infectious Disease and Rheumatology, Oncology Center, Paracelus Medical University Hospital Salzburg, Salzburg, Austria",

year = "2013",

doi = "10.1038/bjc.2013.367",

language = "English",

volume = "109",

pages = "58--96",

journal = "BRITISH JOURNAL OF CANCER ",

issn = "0007-0920",

publisher = "Springer Nature",

number = "3",

}

Gnant, M, Pfeiler, G, Stöger, H, Mlineritsch, B, Fitzal, F, Balic, M, Kwasny, W, Seifert, M, Stierer, M, Dubsky, P, Greil, R, Steger, G, Samonigg, H, Fesl, C & Jakesz, R 2013, 'The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.', BRITISH JOURNAL OF CANCER , vol. 109, no. 3, pp. 58-96. https://doi.org/10.1038/bjc.2013.367

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. / Gnant, M; Pfeiler, G; Stöger, H et al.
In: BRITISH JOURNAL OF CANCER , Vol. 109, No. 3, 2013, p. 58-96.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

AU - Gnant, M

AU - Pfeiler, G

AU - Stöger, H

AU - Mlineritsch, Brigitte

AU - Fitzal, F

AU - Balic, M

AU - Kwasny, W

AU - Seifert, M

AU - Stierer, M

AU - Dubsky, P

AU - Greil, Richard

AU - Steger, G

AU - Samonigg, H

AU - Fesl, C

AU - Jakesz, R

N1 - IIIrd Medical Department with Hematology and Medical Oncology, Hemostaeology, Infectious Disease and Rheumatology, Oncology Center, Paracelus Medical University Hospital Salzburg, Salzburg, Austria

PY - 2013

Y1 - 2013

KW - AUSTRIAN BREAST

KW - THERAPY

KW - TAMOXIFEN

KW - LETROZOLE

KW - WOMEN

KW - AMINOGLUTETHIMIDE

KW - RECURRENCE

KW - SURVIVAL

KW - PROJECT

KW - OBESITY

U2 - 10.1038/bjc.2013.367

DO - 10.1038/bjc.2013.367

M3 - Original Article

C2 - 23868011

SN - 0007-0920

VL - 109

SP - 58

EP - 96

JO - BRITISH JOURNAL OF CANCER

JF - BRITISH JOURNAL OF CANCER

IS - 3

ER -

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. BRITISH JOURNAL OF CANCER . 2013;109(3):58-96. doi: 10.1038/bjc.2013.367